| name = | logo = | type = Private | genre = | foundation = Baltimore, MD | founder = | location_city = Baltimore, MD | location_country = United States | location = | locations = | area_served = | key_people = Ancelmo E. Lopes (CEO), Todd Garner (CFO), Jay Zimmerman (COO), Dr. Harry Leider, MD FACPE (Senior Vice President and Chief Medical Officer), Jay Zimmerman (COO), Joel McEndree (Vice President, Intellectual Property and Program Development), Dr. Ronald C. Baker (Vice President, Toxicology), Dr. James E. Bourland (Laboratory Director), Lori Overstreet (Senior Vice President Marketing and New Products), David Mack (Senior Vice President Human Resources), Regina Morano (Corporate Compliance Officer & Vice President) | industry = Urine Drug Monitoring | products = | services = | revenue = | operating_income = | net_income = | assets = | equity = | owner = | num_employees = | parent = | divisions = | subsid = | slogan = | homepage = http://www.ameritox.com | footnotes = | intl =
}}
Ameritox is a company that provides physicians with urine drug monitoring and reporting services. Headquartered in Baltimore, Maryland, the company also has offices and CLIA-certified laboratories in Midland, Texas and Greensboro, North Carolina.
Ameritox offers urine drug testing and reporting services to help physicians determine if their chronic pain patients are taking their pain medications as prescribed. Physicians use this information to identify potential medication misuse and abuse, and make more informed decions. Ameritox’s customer service and patient management support tools permit physicians to integrate medication monitoring into their practice.
Dr. Harry Leider, MD FACPE, Ameritox's Senior Vice President and Chief Medical Officer, also serves as the President and Chairman of the Board for the American College of Physician Executives (ACPE) - the nation's oldest and largest health care organization for physician executives.
Contents |
Ameritox Ltd. was founded in 1996 in Midland, Texas as Universal Toxicology Laboratories (UTL), a federally certified drug testing facility and medical examiner toxicology laboratory. [1]
UTL identified a growing need for a more detailed way of monitoring the use of long-term pain medications used by patients. The company became Ameritox Ltd. in 2003. Today, Ameritox claims to be the nation's largest provider of pain medication monitoring solutions for physicians.[2]
Tampa, FL - United States Attorney Robert E. O’Neill announced today that Ameritox, Ltd. has agreed to pay $16.3 million in a civil settlement that addresses allegations that it paid kickbacks to providers in order to induce them to refer Medicare business.
The settlement resolves allegations that Ameritox made cash payments to its physician clients from January 1, 2003 through December 31, 2006 to induce the referral of drug testing services. It also resolves claims arising from the offer by Ameritox of free collector personnel to its physician clientele from January 1, 2003 through June 30, 2010, in order to induce the referral of Medicare business. Of the total settlement amount, the federal government will receive $15,486,000 with the balance of $814,000 to be split among various states.
“This settlement marks another notable achievement in our continuing campaign against health care fraud in the Tampa Bay area,” said U.S. Attorney O’Neill. “Working side by side with our law enforcement agencies, we will be extremely diligent in our attempt to eliminate these kinds of practices in our district.” Ameritox also entered into a 5-year Corporate Integrity Agreement (CIA) with the Department of Health & Human Services Office of Inspector General (HHS-OIG). Among other things, the CIA requires the company to engage an independent review organization to scrutinize its contractual relationships.
Rx Guardian CD SM is now part of the Rx Guardian SM process. Rx Guardian CD SM features a unique reference database supported by a proprietary normalization algorithm. Patients’ normalized results are compared against the reference database, giving added confidence in assessing whether patients are taking their medications correctly.
Ameritox and the Jefferson School of Population Health at Thomas Jefferson University conducted a national study to determine the rates of inappropriate use, and likely abuse, misuse and diversion of opioids among chronic pain patients, as measured by urine drug testing in the clinical setting. The results showed that 75% of patients in the study may not have been taking their pain medication consistent with their prescribed regimen. [3]